PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-0.46%
Negative ROE while Drug Manufacturers - Specialty & Generic median is 0.61%. Seth Klarman would investigate if capital structure or industry issues are at play.
-0.40%
Negative ROA while Drug Manufacturers - Specialty & Generic median is 0.03%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-0.68%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is 0.55%. Seth Klarman would investigate whether a turnaround is viable.
32.36%
Gross margin 50-75% of Drug Manufacturers - Specialty & Generic median of 58.39%. Guy Spier would question if commodity-like dynamics exist.
-72.84%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 1.99%. Seth Klarman would look for a path to operational turnaround.
-45.08%
Negative net margin while Drug Manufacturers - Specialty & Generic median is 1.35%. Seth Klarman would see if cost cuts or revenue growth can fix losses.